Warren Wang, MBA ′01

President, North Asia, Boston Scientific Corporation

Mr. Warren Wang is the President of Boston Scientific Corporation for North Asia, responsible for the company’s business operations and development in the region. He is also the Asia Pacific Chairman of Boston Scientific’s Urology/Pelvic Health Council. Warren joined Boston Scientific in 2012 as the Vice President and Managing Director for China, and was appointed Vice President and Managing Director for Greater China in November 2014, responsible for business operations in mainland China, Taiwan, and Hong Kong. Warren joined the Johnson & Johnson Management Trainee Program in 2001. In 2006, he was promoted to head of Johnson & Johnson's DePuy orthopedics and neuro-sciences business, and became a board member of Johnson & Johnson Medical China. He was promoted again to Vice President of Johnson & Johnson Medical China in January 2010 and General Manager of the Johnson & Johnson orthopedics business unit in February 2012. Warren earned a bachelor’s degree in Economics from the University of International Business and Economics, Beijing, and a Master of Business Administration (MBA) in Marketing and Finance from the University of Chicago.

Lieming, Ding

Chairman and CEO, Betta Pharmaceuticals Co., Ltd

Lieming Ding is the chairman and CEO of Betta Pharmaceuticals Co., Ltd with many other titles: distinguished expert of All-China Federation of Returned Overseas Chinese, Deputy of the 12th National Peoples’ Congress, key member of Chinese National Key Special Program of Innovative Drugs, and Chairman of China Pharmaceutical Innovation and Research Development Association (PhIRDA). Lieming Ding came back to China at the middle of 2002 to start up Betta Pharmaceuticals Co., Ltd, a company focusing on research and development of new drugs. In August 2011, Betta Pharmaceutical launched Icotinib (Conmana), the first home-made drug in China for targeted therapy of non-small cell lung cancer, which is the milestone for Chinese anticancer industry. In 2012 and 2014, the WIPO and SIPO of China issued Gold award to Icotinib for its two invention patents. Icotinib won the first prize of the National Science and Technology Progress Award in 2016, which is the first time that the chemical and pharmaceutical industry won the prize. In the same year, Icotinib also won the China Industry Award, the top accolade of industry sector. To date, Icotinib has the total sales revenue of over 3.4 billion RMB and has benefited more than 100,000 patients.

Lana Hu, MD. ,Ph.D., MBA

Founder, CEO Amcare Healthcare Group

Dr. Lana Hu obtained her medical degree from Beijing University Medical School. After graduation, she went to Medical College of Ohio to pursue a Ph.D degree in medical science, particularly in cancer research . Due to her strong interest in business, after Ph.D. study, Dr. Hu earned her MBA degree at University of Michigan Business School. She joined JPMorgan Investment Banking Division in 2002 when she completed her MBA program. At JPMorgan, Dr. Hu was involved in many transactions including M&A advisory, private placement and other public equity deals. Dr. Hu founded Amcare Healthcare Group, and took the role of CEO since then.

Yiqing, Wan

Deputy CEO, China Life Investment Holding Co. Ltd. CEO, China Life Private Equity Investment Co.

Wan Yiqing is the Deputy CEO of China Life Investment Holding Company Limited and also serves as the CEO of China Life Private Equity Investment Company, the alternative asset management arms of the largest insurer in China. Mr. Wan is directly responsible for managing China Life’s onshore and offshore private equity investments, and a standalone healthcare investment business, with collective assets of over RMB 60 billion. Previously, Mr. Wan served as the founding General Manager of China Life’s Private Equity Investment Department, and was responsible for launching the China Life Healthcare Investment Fund with over RMB 12 billion commitment. This Fund has since invested in WuXi AppTec, Mindray, Innovant Biologics, etc. Mr. Wan received his M.A. degree in International Economics from Nankai University in 1997 and an M.S. degree in Computer Science in 2000 from West Virginia University, USA.

Xiaochun, Zhang

Co-Founder, WeDoctor Group

Mr. Zhang Xiaochun was graduated from Dongbei University of Finance & Economics. Since 2000, he has dedicated to the Internet industry. In 2010, he assisted Mr. Liao Jieyuan in founding the Guahao.com (WeDoctor Group) as a co-founder. In his career, Mr.Zhang has been the CEO of Galaxy Internet TV and the general manager of New Media Company of China National Radio.

Adam Sun, MBA ′98

Founding Partner, Ocean Pine Capital

Mr. Adam Jigang Sun is currently the Founding Partner of Ocean Pine Capital, a healthcare-focused private equity fund based in Beijing, China. From September 2011 until July 2016, he has served as the chief financial officer and chief investment officer of Concord Medical Services (NYSE: CCM)，the operator of cancer hospitals and the largest network of radiotherapy and diagnostic imaging centers in China, USA and Singapore. He has served as the Board Chairman of MD Anderson Proton Center, which CCM acquired the controlling ownership in 2012. He has accumulated rich experience in the healthcare sector, especially in cross-border investment and acquisitions. Prior to joining Concord Medical Services, Mr. Sun was the chief financial officer of a subsidiary of Asia Pacific Medical Group from January to September 2011. From 2008 to 2011, he was the Chief Financial Officer of Gongda Chemical Industry Equipment & Systems, a manufacturer of premium chemical systems in China. He started his professional career in the USA with AT Kearney, the management consulting company in Chicago in 1998. Afterwards, he worked at Universal Studios in the function of Business development from 2001 to 2004. From 2004 to 2008, he has founded IA Exchange, Inc., a financial advisory firm to help Chinese companies seeking financing in the USA. Mr. Sun received his MBA degree from the University of Chicago Booth School of Business in 1998 and his bachelor of arts degree in English from China Foreign Affairs College in 1990.